The Department of Defense Ovarian Cancer Research Program (OCRP) offers the Clinical Development Award to translate promising preclinical findings into clinical applications targeting ovarian cancer. The award aims to accelerate the introduction of medical products focusing on prevention, detection, treatment, or quality of life improvements. Projects should have proof-of-concept established, excluding animal preclinical studies. Eligible activities include small-scale clinical trials, enriching existing trials, or projects linked to ongoing/completed trials. Applicants need to provide relevant data supporting the study rationale. Application deadline: August 10, 2016.
Opportunity ID: 282236
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-16-OCRP-CDA |
| Funding Opportunity Title: | DoD Ovarian Cancer Clinical Development Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 3 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 16, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Aug 10, 2016 |
| Current Closing Date for Applications: | Aug 10, 2016 |
| Archive Date: | Sep 09, 2016 |
| Estimated Total Program Funding: | $2,880,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The OCRP Clinical Development Award is intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life. The goal of this award mechanism is to accelerate the clinical introduction of medical products and technologies that target ovarian cancer biology. Near-term clinical impact is expected. Proof-of-concept demonstrating the potential utility of the proposed product or a prototype/preliminary version of the proposed product should already be established; thus, preclinical studies in animals are not allowed. Small-scale clinical trials (Phase 0, Phase 1, Pilot), studies enriching a clinical trial, and projects related to or associated with ongoing or completed clinical trials are allowed. Relevant data, either published or unpublished, that support the study rationale are required. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
301-682-5507
Email:help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 282236 Full Announcement-FY16 OCRP CDA -> OCRP_FY16_CDA_PA_GG.pdf
Packages
| Agency Contact Information: | 301-682-5507 Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00221579 | Mar 16, 2016 | Aug 10, 2016 | View |
Package 1
Mandatory forms
282236 RR_SF424_2_0-2.0.pdf
282236 RR_Budget_1_3-1.3.pdf
282236 RR_KeyPersonExpanded_2_0-2.0.pdf
282236 PerformanceSite_2_0-2.0.pdf
Optional forms
282236 RR_SubawardBudget30_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
